Radiation Pneumonitis Treatment Market

Radiation Pneumonitis Treatment Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

Radiation Pneumonitis Treatment Market Segmented By Risk of Development such as Patient Related Factors and Treatment Related Factors having 4D CT ventilation imaging, Imaging Based Biomarkers: Pre-Treatment FDG and NTCP Modeling (Risk Assessment) Technology

Industry: Healthcare

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Report Type: Ongoing

Report ID: PMRREP32641

Report Price

$ 4900*

Pre Book

Radiation Pneumonitis Treatment: Overview

According to the latest research by PMR, Radiation Pneumonitis Treatment is set to witness a 4.2% growth during the year 2021-2031. Radiation pneumonitis is an inflammation of the lung tissue induced by radiotherapy, thus affecting its therapeutic ratio. The major factor involving the occurrence of radiation pneumonitis include the size of the area receiving radiation treatment.

The demand for radiation pneumonitis treatment is set to increase over the forecast period. This is due to the high incidence of occurrence of symptomatic radiation pneumonitis with incidence rate up to 40% in most patients receiving radiotherapy, as according to the data published by the Journal of European Society for Therapeutic Radiology and Oncology.

What is Driving Demand for Radiation Pneumonitis Treatment?

The demand for radiation pneumonitis treatment is largely based on the risk of development of radiation pneumonitis due to patient related factors as well as treatment related factors. The patient related factors, such as patient age, gender, smoking status, performance status and underlying pulmonary conditions increase the chances of developing radiation pneumonitis.

These factors extend support to the growth in demand for radiation pneumonitis treatment. Essentially, treatment factors such as chemotherapy and immunotherapy have highest risk associated with radiation pneumonitis. These factors propel the need for radiation pneumonitis treatment.

The advancements in the understanding of molecular mechanisms involving the injury of tissues and the novel methodologies for the prevention and treatment of radiation pneumonitis has led to a drive in demand for radiation pneumonitis treatment.

Which factors are likely to augment growth of Radiation Pneumonitis Treatment?

Initially, radiation pneumonitis treatment was done by the use of cortecosteriods. The factors introduced for the management of radiation pneumonitis such as the application of therapies targeting free radical production are the most augmentative factors for radiation pneumonitis treatment.

Additionally, the assessment of treatment factors involving the targeting of cytokine and Growth Factor Expression after radiation will improve the growth of demand in radiation pneumonitis treatment prior to successful clinical models. The adoption of Intensity-modulated Therapy also associates with lower rates of radiation pneumonitis and acts as a supplementary factor for growth in radiation pneumonitis treatment.

U.S. and Canada Radiation Pneumonitis Treatment Outlook

According to the Future Oncology journal data study for the year 2019, the incidence of radiation pneumonitis in the U.S. population accounted for over 12.4% for patients with Stage III non-small-cell lung cancer. This incidence is also associated with the higher healthcare cost of treatment of radiation pneumonitis in the U.S. Government support with programs such as Medicaid have positively influenced the adoption of radiation pneumonitis treatment in the country.

There is an extensive amount of research studies involving the incidence of radiation pneumonitis and its management and treatment in Canada. The institutes such as the Canadian Cancer Society offer specialized treatment plans for the management of radiation pneumonitis in addition to offering knowledge and awareness based on procedures involving radiation therapy.

Europe Demand Outlook for Radiation Pneumonitis Treatment

According to a recent study review by BMC Pulmonary Medicine, patient related habits with regard to smoking can play an evidenced impact on lung tissue post radiation therapy. In the U.K., over 6.7% of patients with Stereotactic Ablative Radiotherapy developed radiation pneumonitis in a 2018 study.

The relation between smoking and development of radiation pneumonitis in the region of Europe has impacted the evaluation of radiation pneumonitis treatment for post-radiation therapy.

Who are the Key Manufacturers and Suppliers of Radiation Pneumonitis Treatment?

The key companies working in radiation therapy and solutions for radiation pneumonitis treatment and management are

  • Provision Healthcare LLC
  • Hitachi Ltd.
  • Elekta AB (pub)
  • C. R. Bard Inc.
  • Optivus Proton Therapy Inc.
  • Mevion Medical Systems Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Isoray Medical Inc.
  • Varian Medical Systems Inc.

Key Segments

By Risk of Development

  • Patient Related Factors
    • Pre-Existing Lung Conditions
      • COPD
      • Asthma
      • Interstitial Lung Disease
    • Smoking Associated Hypoxia
  • Treatment Related Factors
    • Chemotherapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery

By Technology

  • 4D CT ventilation imaging
  • Imaging Based Biomarkers: Pre-Treatment FDG
  • NTCP Modeling (Risk Assessment)

By End User

  • Hospitals
  • Research Centers and Laboratories
  • Research Institutions

By Region

  • North America
    • US
    • Canada
  • Latin America
    • Brazil
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • U.K.
    • Spain
    • BENELUX
    • Russia
  • South Asia
    • India
    • Thailand
    • Malaysia
    • Indonesia
    • Rest of South Asia
  • East Asia
    • China
    • Japan
    • South Korea
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Turkey

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Radiation Pneumonitis Treatment Market Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate